CAS 1033767-86-0

Formula: C17H15N5

InChI: InChI=1S/C17H15N5/c1-9-14(7-18)17(15(8-19)10(2)20-9)12-4-5-16-13(6-12)11(3)21-22-16/h4-6,17,20H,1-3H3,(H,21,22)

InChI key: QKVFMAAIXZONRN-UHFFFAOYSA-N

SMILES: CC1=C2C=C(C=CC2=NN1)C3C(=C(NC(=C3C#N)C)C)C#N

BAY-474

CAS: 1033767-86-0

BAY-474

Formula: C₁₇H₁₅N₅

Purezza: ≥98%

Peso molecolare: 289.33

Ref: 54-BUP08692

2,6-Dimethyl-4-(3-methyl-1H-indazol-5-yl)-1,4-dihydropyridine-3,5-dicarbonitrile

CAS: 1033767-86-0

Formula: C₁₇H₁₅N₅

Purezza: 98%

Colore e forma: Solid

Peso molecolare: 289.3345

Ref: IN-DA01KJXH

BAY-474

CAS: 1033767-86-0

BAY-474 is an inhibitor of tyrosine-protein kinase c-Met. It acts as an epigenetics probe

Formula: C₁₇H₁₅N₅

Purezza: 98.98%

Colore e forma: Solid

Peso molecolare: 289.3345

Ref: TM-T7900

BAY-474

CAS: 1033767-86-0

2,6-Dimethyl-4-(3-methyl-1H-indazol-5-yl)-1,4-dihydropyridine-3,5-dicarbonitrile

Formula: C₁₇H₁₅N₅

Purezza: 99%

Peso molecolare: 289.33

Ref: IN-DG01165701

BAY-474

CAS: 1033767-86-0

BAY-474 is a combination of two active compounds, vegfr and mapk inhibitors. It has been shown to be effective for the treatment of bladder cancer in vitro and in vivo. BAY-474 is administered intraperitoneally for prophylaxis purposes. BAY-474 may also be used for the treatment of other types of cancers that have a high incidence of vascular endothelial growth factor (VEGF) expression, such as nasal cancer. The drug is solvated with an organic solvent, which may help to stabilize the drug's activity and improve its pharmacokinetics.

Formula: C₁₇H₁₅N₅

Purezza: Min. 95%

Peso molecolare: 289.33 g/mol

Ref: 3D-IRB76786